

Please Direct All Correspondence to Customer Number 20995

TRANSMITTAL LETTER

INFORMATION DISCLOSURE STATEMENT


Applicant : Bar-Eli et al.
App. No : 10/660,357
Filed : September 10, 2003
For : USE OF ANTIBODIES AGAINST THE
MUC18 ANTIGEN
Examiner : David J. Blanchard
Art Unit : 1642

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 30, 2005

(Date)


Sheila R. Gibson, Reg. No. 54,120

Mail Stop Amendment

Commissioner for Patents


P.O. Box 1450


Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing twenty-three (23) references.
 - (X) Enclosing sixteen (16) references.
- (X) A check in the amount of \$180 to cover the above fee is enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Sheila R. Gibson
Registration No. 54,120
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Bar-Eli et al.
App. No : 10/660,357
Filed : September 10, 2003
For : USE OF ANTIBODIES AGAIST THE
MUC18 ANTIGEN
Examiner : David J. Blanchard
Art Unit : 1642

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 30, 2005

(Date)

Sheila R. Gibson
Sheila R. Gibson, Reg. No. 54,120

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing twenty-three (23) references to be considered by the Examiner. Also enclosed are sixteen (16) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Sept. 30, 2005


By: *Sheila R. Gibson*
Sheila R. Gibson
Registration No. 54,120
Attorney of Record
Customer No. 20,995
(619) 235-8550

10/05/2005 HDESTA1 00000001 10660357

01 FC:1806

180.00 OP

1965703 : 093005/CAP



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/660,357
	Filing Date	September 10, 2003
	First Named Inventor	Menashe Bar-Eli
	Art Unit	1642
(Multiple sheets used when necessary)	Examiner	David J. Blanchard
SHEET 1 OF 2	Attorney Docket No.	ABGENIX.030C1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,466,468	11/14/1995	Schneider et al.	
	2	5,800,820	09/01/1998	Maione	
	3	6,024,956	02/12/2000	Matsushima et al.	
	4	6,133,426	10/17/2000	Gonzalez et al.	
	5	6,150,584	11/21/2000	Kucherlapati et al.	
	6	6,229,048	05/08/2001	Mazur et al.	
	7	6,342,221	01/29/2002	Thorpe et al.	

FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	8	WO 98/24893 A2	06/11/1998	ABGENIX, INC.		
	9	WO 03/057006 A2	07/17/2003	ABGENIX, INC.		
	10	EP 0 710 719 A	05/18/1996	ABGENIX, INC.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	11	Arenberg et al. "Inhibition of Interleukin-8 Reduces Tumorigenesis of Human Non-Small Cell Lung Cancer in SCID Mice." <i>J. Clin. Invest.</i> , 97(12):2792-2802 (1996).	
	12	Davis, et al. "Transgenic mice as a source of fully human antibodies for the treatment of cancer." <i>Cancer and Metastasis Reviews</i> , 18:421-425 (1999).	
	13	Green et al. "Interleukin-8 (IL-8), Melanoma Growth-stimulatory Activity, and Neutrophil-activating Peptide Selectivity Mediate Priming of the Neutrophil NADPH Oxidase through the Type A or Type B IL-8 Receptor." <i>The Journal of Biological Chemistry</i> , 271(41):25400-25405 (1996).	
	14	Lehmann et al. "MUC18 a marker of tumor progression in human melanoma shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily." <i>Proceedings of the National Academy of Sciences USA</i> , 86:9891-9895 (1989).	
	15	Luca et al. "Expression of Interleukin-8 by Human Melanoma Cells Up-Regulates MMP-2 Activity Increases Tumor Growth and Metastasis." <i>American Journal of Pathology</i> , 4:1105-1113 (1997).	
	16	Mendez et al. "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice." <i>Nature Genetics</i> , 15(2):146-156 (1997).	
	17	Michi et al. "Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells." <i>Oral Oncology</i> , 36:81-88 (2000).	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary) SHEET 2 OF 2	Application No.	10/660,357
	Filing Date	September 10, 2003
	First Named Inventor	Menashe Bar-Eli
	Art Unit	1642
	Examiner	David J. Blanchard
	Attorney Docket No.	ABGENIX.030C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	18	Rofstad et al. "Vascular Endothelial Growth Factor, Interleukin-8, Platelet-derived Endothelial Cell Growth Factor, and Basic Fibroblast Growth Factor Promote Angiogenesis and Metastasis in Human Melanoma Xenografts." <i>Cancer Research</i> , 60:4932-4938 (2000).	
	19	Scott et al. "Atracurium: Clinical strategies for preventing histamine release and attenuating the haemodynamic response." <i>Br. J. Anaesth.</i> , 57:550-553 (1985).	
	20	Shih et al. "A new MEL-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue." <i>Modern Pathology</i> , 11(11):1098-1106 (1998).	
	21	Shih, Le-Ming. "The role of CD146 (MEL-CAM) in biology and pathology." <i>Journal of Pathology</i> , 189(1):4-11 (1999).	
	22	Singh et al. "Ultraviolet B Irradiation Promotes Tumorigenic and Metastatic Properties in Primary Cutaneous Melanoma via Induction of Interleukin 8 ¹ ." <i>J. Cancer Research</i> , 55:3669-3674 (1995).	
	23	Yang et al. "Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy." <i>Critical Reviews in Oncology-Hematology</i> , 38(1):17-23 (2001).	

1965353 : 093005/CAP

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.